Duke University and Affymetrix Initiate Five-Year Translational Research Collaboration
News Jan 10, 2006
Affymetrix Inc. has announced that it has entered into five-year collaboration with Duke University to analyze genomic information across large patient samples.
Under terms of the agreement, Duke researchers will use Affymetrix GeneChip® microarray technology to develop applications for translational research projects. The initial projects will focus on cancer and cardiovascular disease.
Duke researchers will use Affymetrix's GeneChip HT System and arrays to perform large-scale clinical studies.
The Affymetrix technology will enable them to discover RNA and DNA patterns that can better classify, manage and treat complex diseases.
As part of the agreement, Affymetrix will fund creative research and clinical projects that could lead to new genomic applications on the GeneChip platform, as well as diagnostics and screening tests.
"This is an exciting time when genomics offers the promise of a deeper understanding of biology while at the same time improving the practice of medicine," said Joseph Nevins, Ph.D., director of the IGSP Center for Applied Genomics & Technology at Duke University.
"By combining our research expertise with Affymetrix's high-throughput microarray technology, we have the opportunity to build on our prior work and develop gene expression profiles that characterize oncogenic pathways and define tumor phenotypes, which are important in determining clinical outcomes."
"At the same time, this can translate into improved clinical care and provide an important resource to enhance the use of microarray technology for all Duke investigators."
"Affymetrix is excited to be working with a leading research organization such as Duke University to help bring more effective personalized tests and therapies to market faster," said Gregg Fergus, senior vice president, Global Sales Operations at Affymetrix.
"Together, we hope to accelerate clinical research, improve patient care and open the door to new genomic applications."
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018